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(CXCL12) and its receptor CXCR4 may play an important
role in the regulation of anterior pituitary function. In
this study, we investigated the expression of CXCL12
and CXCR4 and their role in normal rat pituitary and
GH-producing GH3 tumor cell line. RT-PCR analysis and
immunohistochemistry revealed that CXCR4 was expressed
in normal rat anterior pituitary and GH3 tumor cells. Double
immunofluorescent staining showed the complete colocaliza-
tion of CXCR4 with GH in rat pituitary, indicating that
CXCR4 is specifically expressed in rat somatotrophs. Using
rat primary pituitary cell cultures and GH releasing hormone
receptor expressing stable GH3 cells (GH3-GHRHR), we
evaluated the function of CXCL12 compared with GHRH.Journal of Endocrinology (2008) 199, 191–199
0022–0795/08/0199–191 q 2008 Society for Endocrinology Printed in GreatCXCL12 stimulated GH gene activation in both primary rat
anterior pituitary cells and GH3-GHRHR cells. CXCL12
also stimulated GH secretion from primary rat pituitary cells
in a dose-dependant manner. BrdU incorporation was
increased in response to CXCL12 addition in GH3 cell
culture, indicating CXCL12-induced cell proliferation.
CXCL12-dependent phosphorylation of ERK1/2 was also
confirmed by western blot analysis, supporting the evidence
that MAPK is an intracellular mediator of CXCL12/CXCR4
interaction in GH3 cell proliferation. In conclusion, these
results indicate that CXCL12/CXCR4 interaction plays an
important role in GH production, secretion, and the
proliferation of somatotrophs.
Journal of Endocrinology (2008) 199, 191–199Introduction
The neural and endocrine systems are sophisticatedly
connected through small molecules such as neurotransmitters,
neuropeptides, and cytokines including chemokines.
Chemokines, or ‘chemotactic cytokines,’ are small secreted
proteins (6–10 kDa) that have the ability to dictate the
migration and activation of leukocytes (Bajetto et al. 2001).
Recently, several reports have suggested that some chemo-
kines and their receptors are expressed in the brain as well as
inflammatory sites and might function as neurotransmitters or
neuromodulators in the central nervous system (Callewaere
et al. 2007, Rostene & Buckingham 2007). Chemokine (C-
X-C motif) ligand 12 (CXCL12/CXCL12) was originally
cloned from a murine bone marrow stromal cell line (Tashiro
et al. 1993), and its amino acid sequences are highly conserved
during evolution, implying that this substance might play an
important biological role. CXCL12/CXCR4 interaction has
been shown to be involved in the embryologic development
of the vascular, cardiac, hematopoietic, and central nervoussystems (Ma et al. 1998, Tachibana et al. 1998, Stumm et al.
2003), and is associated with tumor cell proliferation or
migration (Hall & Korach 2003, Bajetto et al. 2006, 2007).
After CXCL12 binding sites were discovered in the adult rat
pituitary gland by autoradiographic assay using I131 labeled
CXCL12 (Banisadr et al. 2000), a group demonstrated that
CXCL12 stimulated cell proliferation and growth hormone
(GH) secretion in the rat pituitary adenoma-derived cell line
GH4C1 (Florio et al. 2006, Massa et al. 2006), suggesting that
interaction between CXCL12 and CXCR4 regulates the
function of the anterior pituitary gland. Furthermore, it has
recently been reported that CXCL12 and CXCR4 are
expressed in theposterior pituitary neurons and their interaction
is important for regulating arginine vasopressin (AVP) secretion
(Callewaere et al. 2006). In this study, we demonstrated the
colocalization of CXCR4 with rat pituitary somatotroph and
investigated the role of CXCL12/CXCR4 interaction on the
secretion and production of GH and cell proliferation in
both normal rat pituitary and rat pituitary somatotroph tumor
GH3 cells.DOI: 10.1677/JOE-08-0250
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RNA isolation and RT-PCR for Cxcl12 and Cxcr4
Expression ofCxcl12mRNA andCxcr4mRNAwas analyzed
by RT-PCR using total RNA isolated from rat pituitary
tissues and GH3 cells. RNA was extracted using TRIZOL
reagent (Invitrogen Corp.) as described by the manufacturer’s
instructions. 20 mg RNA were treated with RNase-free
DNase-I (QIAGENKorea Ltd) for 10 min at 25 8C. Random
hexamers were used to synthesize single-stranded cDNA
using 2 mg DNase-I treated RNA in a 20 ml reaction volume
containing 50 mM of Tris–HCl, pH 8.3, 8 mM MgCl2,
50 mM NaCl, 1 mM dithiothreitol, 1 mM dNTPs, 22 U
RNase inhibitor, and 10 U moloney murine leukemia virus
(MMLV) RT (Promega) for 60 min at 37 8C. A portion
(1/40) of cDNA solution was treated with 2.5 U Taq DNA
polymerase (Promega Corp.) for amplification of CXCL12,
CXCR4, and GAPDH as a control. Cycle conditions were:
2 min hot start at 96 8C, followed by 35 cycles of 1 min at
94 8C, 45 s at 55 8C, followed by 1 min at 72 8C, and
extension at 72 8C for 15 min. An aliquot (20%) of each PCR
product was resolved by electrophoresis on 1.5% agarose gels
and DNA products were visualized with ethidium bromide.
Oligonucleotides used for PCR amplification were:
CXCL12, forward 5 0-CAT GGA CGC CAA GGT CGT-
3 0 and reverse 5 0-TCC AGG TAC TCT TGG ATC CA-3 0;
CXCR4, forward 50-CAAGCAAGGATGTGAGTTCG-30
and reverse 5 0-GCT GGA GTG AAA ACT TGA GG-3 0;
GAPDH (390 bp), forward 5 0-CCA AAG TTG TCA TGG
ATG AC-3 0 and reverse 5 0-CCC TTC ATT GAC CTC
AAC TA-3 0.Immunohistochemistry and immunofluorescence
Immunohistochemical study for the expression of CXCL12
andCXCR4was performed using paraffin-embedded pituitary
glands of Sprague–Dawley rats. 5 mm sections of the pituitary
were prepared. After deparaffinization and hydration of the
slides, peroxidase quenching was performed with 3% hydrogen
peroxide in PBS for 10 min. After preincubation with serum
blocking solution (ZymedLaboratories Inc., SanFrancisco,CA,
USA) containing 5% horse serum, specimens were incubated
with mouse monoclonal anti CXCR4 (5 mg/ml, sc-12764,
SantaCruzBiotechnology Inc., Burlingame,CA,USA) or anti-
CXCL12 antibody (10 mg/ml,R&DSystem Inc.,Minneapolis,
MN, USA), which are compatible to human and rat species for
3 h at room temperature. After washing the slides with tris-
buffered saline/0.025% Tween, biotinylated horse anti-mouse
immunoglobulin (5 mg/ml, Vector Laboratories, Inc., Burlin-
game, CA, USA) and streptavidin-peroxidase conjugate
(Vector Laboratories) were added sequently. DAB (diamino-
benzidene; DAKOCorp., Carpinteria, CA, USA) was used as
a chromogen. We also tested other anti-CXCR4 antibodies
originated from goat (N-terminus specific, sc-6279, Santa
Cruz) that can detect CXCR4 of the human, rat, and mouse.Journal of Endocrinology (2008) 199, 191–199Immunoglobulin G originated from mouse and goat was used
as negative controls against anti-CXCR4 antibody. We used
two different tissue controls including the posterior lobe for
positive control and adrenocorticotrophin (ACTH)-secreting
human pituitary tumor for negative control. CXCR4 was
detected in the posterior lobe (Fig. 1C), whereas this was not
detected in ACTH secreting pituitary tumor tissues (data not
shown).
Double immunofluorescent staining was performed to
colocalize CXCR4 with pituitary hormones including GH
and prolactin (PRL). After preincubation with serum
blocking solution (10% donkey serum), rabbit polyclonal
anti-human GH (1:50; Zymed Laboratories) and goat
polyclonal anti-PRL (2 mg/ml 1:100; Santa Cruz Bio-
technology) were used to detect somatotrophs and lacto-
trophs, respectively. Anti-CXCR4 antibody was used as
described above. After incubation for 3 h with the primary
antibodies, staining was performed using fluorescent labeled
secondary antibodies (1:100, Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA) including fluor-
escein isothiocyanate (FITC) donkey anti-mouse immuno-
globulin, FITC donkey anti-goat immunoglobulin, Texas
Red donkey anti-rabbit immunoglobulin, and Texas Red
donkey anti-goat immunoglobulin. To minimize autofluor-
escence, slides were incubated in 70% ethanol supplemented
with 0.1% sudan black B for 15 min and washed vigorously in
running water. Fluorescent mounting media (Vector Labora-
tories) containing 4 0,6 0 diamidino-2 phenylindol was used for
nuclei-counterstaining and mounting.
To detect the expression of CXCR4 or GHRHR in GH3-
GHRHR cells, cells were plated on fibronectin-coated cover
slips and washed with PBS twice, then fixed with 4%
paraformaldehyde in PBS (pH 7.4) for 5 min. The slides were
incubated with rabbit anti-human GHRH (hGHRH) receptor
(1:1000; provided by Dr Bruce Gaylinn, University of Virginia,
Charlottesville, VA, USA) or mouse monoclonal anti-CXCR4
at room temperature for 1 h. After washing, staining was
performed using biotinylated secondary antibodies (Vector
Laboratories), and streptavidin-FITC (1:100; Vector Labora-
tories). Images were obtained using a Zeiss microscope
(Axioskop, Carl Zeiss Inc., Oberkochen, Germany).Establishment of stable GH3 cells expressing GHRHR
GH3 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and grown in Dulbecco’s
Modified Eagle Medium (DMEM)/Ham’s F-12 containing
10% FBS. All media were supplemented with 100 U/ml
penicillin and 100 mg/ml streptomycin, and maintained at
37 8C with 5% CO2. Stable GH3-GHRHR were selected.
Briefly, GH3 cells at 70% confluency were transfected with
pCDNA3 carrying hGHRHR cDNA (provided by Kelly E
Mayo, Northwestern University, Chicago, IL, USA) using
low-serum Opti-MEM (Invitrogen Corp.) and lipofectamine
2000 (Invitrogen Corp.) for 4–5 h. The transfected cells were
washed and incubated in DMEM/Ham’s F-12 mediumwww.endocrinology-journals.org
Figure 1 Expression of CXCL12 and CXCR4 in rat pituitary and
GH3 cells. A) RT-PCR analyses of Cxcl12 and Cxcr4 mRNA in rat
pituitary and GH3 cells were performed. Amplification of GAPDH
mRNA was used as a control. Rat P, pituitary glands of Sprague–
Dawley rats; GH3, GH producing GH3 pituitary adenoma cells. B)
Immunofluorescent assay using anti-CXCR4 antibody (stained with
red) was performed on GH3 cells. Control indicates GH3 cells
incubated with mouse IgG for primary antibody (left). Nuclei were
counterstained with DAPI. Magnification, 630!. C) Immunohisto-
chemical analyses of CXCL12 and CXCR4 in the pituitary of
Sprague–Dawley rats. The left column shows the distribution of
CXCL12-positive cells and the right column shows the localization
of CXCR4-expressing cells. CXCL12 immunostaining was only
observed in the posterior lobe of the pituitary (arrows in the bottom
panel of left column) and remnants of neural tissues (stained in dark
brown in the second picture of left column). A strong CXCR4
immunostaining is observed in rat pituitary tissue, particularly in the
anterior pituitary cells. No CXCL12- or CXCR4-positive cells were
detected in the intermediate lobe of pituitary glands. A, anterior
pituitary; P, posterior pituitary; I, intermediate lobe of rat pituitary.
Magnification, top panels, 25!; middle panels, 200!; bottom
panels, 400!.
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www.endocrinology-journals.org(GIBCO BRL) containing 300 mg/ml of Geneticin (G418,
Life Technologies). GH3-GHRHR cells that grew into
monoclones were selected from the media and transferred to
other plates. Each selected monoclone was harvested and the
expression of GHRHR was confirmed by RT-PCR, western
blot analysis, and immunofluorescent staining.Western blot analysis
GH3-GHRHR cells in 10 cm plates were lysed in radio-
immunoprecipitation assay (RIPA) buffer (20 mM Tris,
2 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 5%
phosphatase inhibitors, 0.5% protease inhibitors) and protein
content was measured using Coomassie (Bradford, UK)
Protein Assay Kit (Pierce, Rockford, IL, USA). Equal
amounts of protein (10 mg) were heat denatured in 2X
sample buffer (2% SDS, 62.5 mM of Tris, pH 6.8, 0.01%
bromphenol blue, 1.43 mM mercaptoethanol, and 0.1%
glycerol), separated on 10% SDS-polyacrylamide gel,
transferred onto polyvinylidene difluoride (PVDF) mem-
brane (Bio-Rad), and blotted with the appropriate antibodies:
anti-hGHRH receptor antibody, p44/42 MAPK (ERK1/2)
antibody, and phosphor-p44/42 MAPK antibody (Cell
Signaling Technology Inc). Detection of immunocomplexes
was performed by enhanced chemiluminescence system (Cell
Signaling Technology Inc., Danvers, MA, USA).Luciferase assay
To determine whether CXCL12 is involved in GH-gene
promoter activity, GH3-GHRHR cells were seeded in 12-well
plates at a density of 5!105 cells/well, then plasmids containing
the human GH promoter (K610,C58 from transcription start
site; Lee & Jameson 2002) luciferase constructs were transfected
using lipofectamine 2000 according to the manufacturer’s
instructions. The transfected cells were treated with SDF1b
(1.8!10K8 M, Human/Feline CXCL12/SDF-1b, 96%
identical with rat, R&D Systems, Inc.), hGHRH (1–29; 10K9
M, Sigma–Aldrich Inc.), and somatostatin (10K7 M, Sigma–
Aldrich) in serum-free medium for 16 h, then lysed for assay of
luciferase activities (Luciferase Assay System, Promega).
Relative light units were determined using MicroLumat
LB96PEG&G luminometer (Berthold Technologies, Bad
Wildbad, Germany). Luciferase activity was normalized as
described previously (Ishikawa et al. 2004).Real-time PCR
To assess the level of gene expression, real-time RT-PCR was
carried out on the experimental samples using ABI 7300
Sequence Detection System (Perkin–Elmer Applied Bio-
systems, Foster City, CA, USA). The synthesized cDNAs,
obtainedby themethoddescribed above,were further amplified
in triplicate by PCRusing SYBRGreen I as fluorescent dye and
1!PCR Master Mix (Takara Bio Inc., Tokyo, Japan)
containing 300 nmol of forward and reverse primers in a finalJournal of Endocrinology (2008) 199, 191–199
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normalization ofGHmRNA level. The gene-specific primers
used forGH amplification were: forward 50- GCT GCGTTC
TGC TTC TCAG-30 and reverse 50- CCG AGG TAC CAA
ACA TCA G-3 0. PCR cycling conditions were: initial
denaturation and enzyme activation at 95 8C for 5 min,
followed by 40 cycles of denaturation at 95 8C for 15 s,
annealing at 60 8C for 15 s, and extension at 72 8C for 1 min.
Calculation of relative expression levels of the target mRNAs
was conducted based on the cycle threshold (CT) method
(Higuchi et al. 1993). The CT for each sample was calculated
using ABI 7300 Real-time PCR detection system software
with an automatic fluorescence threshold setting.Primary rat pituitary cell cultures and measurement of GH
Anterior pituitary glands from male Sprague–Dawley rats
(250–300 g, 8 weeks old, Orient Bio Inc., Kyoungki, Korea)
were obtained after careful removal of the posterior pituitary
described previously (Colin & Jameson 1998) and dispersed
by enzymatic digestion for 15 min in 0.125% trypsin
(Worthington Biochemical Corp., Lakewood, NJ, USA)/
PBS solution containing no calcium and magnesium ions
with shaking. Ten U/ml of DNAse-I (Sigma–Aldrich) were
added to the solution and incubated for 2 min. Cells were
treated with 0.125% collagenase type IV (Sigma–Aldrich) for
5 min and filtered and washed with DMEM (Hyclone, UT,
USA), then plated in 12-well culture plates in a mixture of
DMEM (Hyclone) supplemented with 10% FBS, 100 U/ml
of penicillin, and 100 mg/ml of streptomycin for 48 h.
Rat anterior pituitary cells were maintained in serum-free
DMEM for 1 h before the experiment. Then, serum-free
DMEM containing SDF1b (18 nM), GHRH (1 nM), or both
CXCL12 and GHRHwas replaced, aliquots were collected at
30, 60, and 120 min, and stored atK70 8C. The levels of GH
in culture medium were measured using a rat GH RIA kit
(LINCO Research, Inc., St Charles, MO, USA).
Animal experiment and protocol were approved by
Institutional Animal Care and Use Committees of Yonsei
University, College of Medicine.BrdU incorporation analysis of GH3 cells
GH3-GHRHR cells were plated at 5!104/well in 96-well
plates, serum starved for 48 h before being treated with
SDF1b for 16 h, and in the last 2 h, cells were incorporated
with BrdU. Cell proliferation was measured by BrdU
incorporation assay according to the manufacturer’s protocol
(Chemicon International, Temecula, CA, USA).Statistical analyses
Data are presented as the meanGS.D. The statistical
significance of differences was analyzed by Student’s t-test
for comparison between control and experiment groups.
P!0.05 was considered statistically significant. StatisticalJournal of Endocrinology (2008) 199, 191–199analyses were performed using SPSS for Windows software
(version 12.0; SPSS, Chicago, IL, USA).Results
Expression of CXCL12 and CXCR4 in rat pituitary
and GH3 cells
To evaluate the putative role of the CXCL12/CXCR4 system
in the function of pituitary, expression of chemokine receptor
CXCR4 and its natural ligand CXCL12 was studied in the
pituitary gland of Sprague–Dawley rats and GH3 cells.
RT-PCR analysis showed that Cxcr4 mRNAwas detected in
both rat pituitary and GH3 cells whereas Cxcl12 mRNAwas
expressed only in rat pituitary tissues that contained neurons of
the posterior pituitary. Immunofluorescent staining showed
that CXCR4 was localized along the membrane of GH3 cells
(Fig. 1B), while CXCL12 was not detected (data not shown).
Immunohistochemical staining of rat pituitary glands revealed
that a number of cells were stained with anti-CXCL12 and
anti-CXCR4 antibodies in the posterior pituitary whereas
CXCL12 positive cells were not observed in the anterior and
intermediate lobe. A large number of cells in the anterior and
posterior lobe were stained with anti-CXCR4 antibody,
whereas the intermediate lobe was not stained at all. The
intensity of positivity in the anterior pituitary is stronger
compared with that in the posterior pituitary (Fig. 1C). Using
different antibody and control IgGs originating from mouse
and goat, the same results were obtained (data not shown).Colocalization of CXCR4 with GH in rat pituitary
Because a large number of anterior pituitary cells were
positive for CXCR4 by immunohistochemical staining, we
investigated whether they were somatotroph or lactotroph.
Double immunofluorescent staining revealed that CXCR4
expression was strictly colocalized with GHwhereas PRL was
not colocalized at all (Fig. 2). This finding suggests that
CXCR4 is specifically expressed in the somatotroph of the
anterior pituitary.Activation of GH gene by Cxcl12 in GH3-GHRHR and
primary rat pituitary cells
To investigate the role of CXCR4/CXCL12 interaction on
GH gene activation in primary rat pituitary cell cultures and
GH3 in comparison with GHRH and somatostatin, which
are major regulators of production and secretion of theGH in
the somatotroph, we examined the activity of the GH
promoter by luciferase assay and the expression of GH
mRNA by real-time PCR. Because GH3 cells do not possess
receptors for GHRH (Zeytin et al. 1984), stably transfected
GH3 cells with hGHRHR (GH3-GHRHR) cells were
established. RT-PCR and western blot analysis were
performed to assess hGHRHR expression in 4 cloneswww.endocrinology-journals.org
Figure 2 Colocalization of CXCR4 with GH in rat anterior pituitary. Double immunofluorescent staining of
CXCR4 with GH or PRL was performed in the rat anterior pituitary. CXCR4 positivity (FITC) strictly colocalizes
with GH-positive somatotroph (Texas-red) in the anterior pituitary (upper panel). CXCR4-positive cells (Texas
Red) were not colocalized with PRL positive lactotroph (FITC). Magnification, upper and lower panels, 400!;
scale bar, 50 mm.
Figure 3 Expression of GHRHR in GH3-GHRHR cells. A) RT-PCR
(upper panel) and western blot analysis (lower panel) of the hGHRH
receptor in stably transfected GH3 cells with hGHRHR (GH3-
GHRHR), and hGHRH receptor mRNAwas detected atw300 bps.
Lanes 1–4 indicate the different clones of GH3-GHRHR cells. B)
Immunofluorescent localization of the hGHRH receptor. Immuno-
fluorescent staining of GH3-hGHRHR cells (clone 4) was
performed using rabbit anti-hGHRHR receptor antibody (stained
with red). Left, Mock-transfected GH3 cells; right, GH3-GHRHR
cells (clone 4). Magnification, 400!.
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was detected in GH3-GHRHR cells and an additional band
of higher molecular weight was also observed, presumably
corresponding to a different form of glycosylated hGHRHR
(Fig. 3A; Lee et al. 2001). Immunofluorescent staining
showed that expression of hGHRH receptor was readily
detected in membranes of GH3-GHRHR cells (clone 4;
Fig. 3B). Experiments were then performed using clone 4.
The activity ofGH promoter in GH3-hGHRHR cells was
measured by luciferase assay to determine whether
CXCR4/CXCL12 signaling stimulates the GH promoter.
SDF1b (18 nM) and GHRH (1 nM) increased luciferase
activity (about 85 and 20% increments respectively; Fig. 4A).
Interestingly, addition of both ligands increased luciferase
activity slightly. Luciferase activity was declined in somato-
statin-treated cells compared with the control group, implying
an inhibitory effect of somatostatin on GH transcription.
These findings indicate that SDF1b and GHRH increase GH
promoter activity in GH3-GHRHR cells.
Real-time PCR analysis was performed to evaluate the
effect of SDF1b onGHmRNAexpression in GH3-GHRHR
cells and primary rat anterior pituitary cells in culture. SDF1b
stimulated GH mRNA expression in both GH3-GHRHR
cells (2-fold) and primary rat anterior pituitary cells (3-fold;
Fig. 4B and C). GHRH addition also stimulated GH mRNA
expression (1.5-fold) in both cells. The activated levels
(1.5–2.0-fold) of GH mRNA by the addition of both ligands
were similar to those by GHRH addition.www.endocrinology-journals.org Journal of Endocrinology (2008) 199, 191–199
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pituitary cells
To investigate whether CXCL12 stimulates GH secretion in
primary rat anterior pituitary cells, measurement of GH in
culture media was performed after treatment of SDF1b or
GHRH (Fig. 5). The posterior pituitary was carefully
removed before culturing to minimize the effect of
endogenous CXCL12 secreted from the posterior pituitary.Journal of Endocrinology (2008) 199, 191–199SDF1b significantly stimulated the secretion of GH at 30 and
60 min up to 2.5–3.5-fold compared with the control. GH
was also increased after GHRH alone (2-fold) or co-treat-
ment (3.0-fold) of SDF1b and GHRH.CXCL12 stimulation of GH3 cell proliferation through
ERK1/2 pathway
Proliferation of GH3-GHRHR cells was examined by BrdU
incorporation assay after treatment of SDF1b, GHRH, or
somatostatin for 16 h (Fig. 6A). GH3-GHRHR cells were
maintained in serum-free medium to avoid a possible
proliferative effect of various growth factors. As previously
reported GHRH has a mitogenic effect on GH3 cells
expressing GHRH receptors (Lee et al. 2001), SDF1b and
GHRH significantly stimulated the proliferation of GH3-
GHRHR cells by 30% compared with the control whereas
somatostatin reduced cell proliferation slightly.
To identify the possible intracellular signaling pathways
involved in proliferation of GH3 cells, western blot analysis
was performed to evaluate the effect of SDF1b on
phosphorylation of ERK1/2. Phosphorylation of ERK1/2
occurred in GH3 cells 5 min after addition of SDF1b. This
result is similar to that of a previous report using GH4C1 cells
(Massa et al. 2006).Discussion
Chemokines are proinflammatory chemoattractant cytokines
that play fundamental roles in the immune system by
trafficking and regulating different types of cells related to
inflammation and development. Among more than 50
different chemokines, CXCL12 and its exclusive receptor
CXCR4 have been intensively studied in the fields of
neurology and oncology. Interactions between CXCL12 and
CXCR4 have various effects on cell proliferation, anti-
apoptosis, tumor vascularization, and cell migration (metas-
tasis; Kryczek et al. 2007). In addition, CXCL12 is reported to
be a key molecule involved in developing the central nervousFigure 4 Effect of CXCL12 on activation of GH promoter and GH
mRNA. A) Transcriptional activities of GH promoter in GH3-
GHRHR cells stimulated by various substances were evaluated
using luciferase reporter system. GH3-GHRHR cells were tran-
siently transfected with plasmids containing GH promoter-lucifer-
ase constructs. Cells (5!105 cells/well) were treated with SDF1b
(18 nM), GHRH (1 nM), and somatostatin (100 nM) in serum-free
medium for 16 hr, lysed, and relative luciferase activities (RLA) were
calculated. *P!0.05 as compared with control. B, C) Relative GH
mRNA expression in GH3-GHRHR cells (B) or rat anterior pituitary
cells (C) following SDF1b and GHRH administration. Real-time
RT-PCR was performed at 1 h after treatment with SDF1b (18 nM) or
GHRH (1 nM). GAPDH served as a reference gene used for
normalization of GH mRNA level. *P!0.05 as compared with
control. Results (A–C) were averaged from three independent
experiments and plotted as meanGS.D. for triplicate wells.
www.endocrinology-journals.org
Figure 5 Effect of CXCL12 on GH secretion in rat anterior pituitary
cells. The level of GH secreted from rat anterior pituitary cells
treated with SDF1b (18 nM), GHRH (1 nM), or both was measured
at 60 min by rat GH RIA. GH level was also measured at 30 min
after treatment of SDF1b. Results were averaged from 3 indepen-
dent experiments and plotted as meanGS.D. for triplicate wells.
*P!0.05 as compared with control.
Figure 6 Effect of CXCL12 on cell proliferation of GH3-GHRHR
cells. A) Proliferation of GH3-GHRHR cells was assessed by BrdU
incorporation assay. BrdU-positive cells were detected by ELISA kit
and represented as a relative percentage compared with the control
group. SDF1b (18 nM) and GHRH (1 nM) increased cell prolifer-
ation by 30 and 27% respectively, whereas somatostatin reduced
cell proliferation slightly. Results were averaged from three
independent experiments and plotted as meanGS.D. for triplicate
wells. *P!0.05 when compared with control. B) Activation of
ERK1/2 by CXCL12 in GH3-GHRHR cells. Western blot analysis
was performed to examine phosphorylation of ERK1/2 using a
specific anti-phosphorylated ERK 1/2 antibody after CXCL12
treatment for 5 min. Upper panel, phosphor-ERK1/2; lower panel,
total form of ERK 1/2.
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campus, cerebellum, and hypothalamus (Lazarini et al. 2003).
However, few studies to date have investigated the possible
role of CXCL12/CXCR4 signal in the pituitary. Since low
densities of CXCL12 binding sites were detected in rat
pituitary gland (Banisadr et al. 2000), Florio et al. only
reported that SDF1a induces cell proliferation and GH
secretion in the rat pituitary adenoma-derived cell line
GH4C1 (Florio et al. 2006, Massa et al. 2006). The GH4C1
cell line, established from GH3 cells that produce PRL and
large amounts of GH, expresses low basal levels of GH but
higher PRL levels (Tashjian et al. 1968, 1970). According to
the evidence that GH4C1 cell responses to IGF1 were
opposite to those of GH3 cells or primary rat pituitary cells
(Castillo & Aranda 1997), GH3 cells may be more similar to
normal somatotrophs in characteristics compared with
GH4C1 cells. Our experiments were conducted using
primary rat pituitary cells and GH3 cells, which are known
as valuable sources for studies of hormonal secretory
physiology and signal transduction pathways (Lee et al. 2001).
Expression of CXCL12 and CXCR4 was determined in
the pituitary of Sprague–Dawley rats and GH3 pituitary
tumor cell lines in our study. In contrast to the finding that rat
pituitary cells produced Cxcl12 and Cxcr4 mRNA, only
7-transmembrane receptor CXCR4 was localized along
membranes of GH3 cells. Immunostaining showed that
CXCL12- and CXCR4-positive cells were observed in the
posterior pituitary glands, which contained neurons projected
from hypothalamic nuclei, and was consistent with a previous
report (Callewaere et al. 2006). However, in our results, the
anterior pituitary was strongly stained with anti-CXCR4
antibodies. The anterior pituitary consists of various types of
endocrine cells. Among them, somatotrophs and lactotrophs
are 2 major cell components. However, it is notable that only
somatotrophs possess receptors for CXCL12, confirmed bywww.endocrinology-journals.orgdouble immunofluorescent staining. This result was demon-
strated for the first time in the rat pituitary gland. This result
suggests that CXCR4 could play a role in normal
physiological function of the somatotroph.
In our study, SDF1b increased transcription ofGHmRNA
by activating GH promoter in GH3 cells expressing
GHRHR. There are two splice forms of CXCL12,
designated as SDF1a and SDF1b, which are identical in the
first 89 amino acid (AA) sequences, but SDF1b has 4
additional AA at the C-terminus (Tashiro et al. 1993, Shirozu
et al. 1995). The first 17AA, which are important to the
binding ability of CXCL12 to CXCR4 (Loetscher et al. 1998,Journal of Endocrinology (2008) 199, 191–199
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SDF1a is more sensitive to proteolysis by serum CD26/
dipeptidyl peptidase than SDF1b (De La Luz Sierra et al.
2004), implying the differences in functions or regulatory
roles in vivo. Furthermore, SDF1b is extensively expressed
throughout the rat brain, especially in cerebral endothelial
cells, while SDF1a is localized in specific neuronal structures
such as cingulate (Stumm et al. 2002). In the present
experiments, we chose SDF1b, which showed about a
2-fold potency, compared with SDF1a (Crump et al. 1997),
and are generally distributed over entire brain area.
We observed that the activation of GH promoter or GH
mRNA expression by SDF1b in GH3-GHRHR cells was
higher than by GHRH. This difference might be due to the
relatively low concentration of GHRH (1 nM) compared
with the relatively higher concentration of SDF1b (18 nM)
although we used 1 nM GHRH before (Lee et al. 2001).
Barbieri et al. (2007) showed that similar levels of GH
increases were achieved using 12.5 nM of SDF1a or 300 nM
of GHRH in GH4C1 cells. It is intriguing to predict the
actual concentrations of chemokine CXCL12 and hormone
GHRH in the microenvironment of the pituitary in vivo.
We examined the effects of SDF1b on synthesis and secretion
of GH in primary rat anterior pituitary cells for the first time.
Although anterior pituitary glands consist of heterogeneous
groups of endocrine cells, only somatotrophs in the anterior
pituitary expressed the receptor CXCR4, according to double
immunofluorescent studies (Fig. 2). After the administration of
SDF1b, transcription of GH mRNA and release of GH were
significantly increased compared with those induced by GHRH.
Higher GH secretion was maintained up to 2 h by time-
dependent manner after treatment (data at 120 min not shown).
Interestingly, no synergistic or additive effects onGH secretion or
GH mRNA transcription were observed after administration of
both SDF1b and GHRH, suggesting that CXCL12/CXCR4
signaling and GHRH-mediated pathway may possess the same
intracellular mediators or interferewith eachother.AfterGHRH
binds to Gs protein-coupled GHRHR in the membrane of
somatotrophs, activated adenylyl cyclase produces intracellular
cAMP, followed by secretion ofGH.Although SDF1b inducesG
inhibitory protein-linked reduction in concentrations of cAMP
in cytoplasm (Zheng et al. 1999, Peng et al. 2004, Florio et al.
2006), increased intracellular calcium levels stimulated by SDF1b
may be related to GH release. Further study is needed to clarify
this mechanism.
We demonstrated the mitogenic effect of SDF1b in GH3
cells using BrdU incorporation assay. GH3 cell proliferation
was significantly increased after treatment with SDF1b, which
induced phosphorylation of ERK1/2. CaCC-independent
activation of ERK1/2 and CaCC-dependent stimulation of
cytosolic tyrosine kinase, Pyk2, were reported to be important
SDF1a-related intracellular signaling pathways that mediate
growth of pituitary GH4C1 cells (Florio et al. 2006,Massa et al.
2006). Furthermore,CXCL12 increases the percentage of cells
in the S phase and inhibits tumor cell apoptosis by activation of
NF-kB (Helbig et al. 2003, Kryczek et al. 2007). Based onJournal of Endocrinology (2008) 199, 191–199evidence that various kinds of tumor cell proliferations are
associated with CXCL12 (Scotton et al. 2002, Barbero et al.
2003, Hall & Korach 2003), development of the pituitary
tumor may be related to CXCL12-mediated intracellular
pathways. Pituitary tumors are known to derive from the
transformed single pituicyte in which initiating mutations of
candidate genes such as Ras or Gsp have caused a gain of
proliferative functions, followed by clonal expansion stimu-
lated by promoting factors such as locally produced growth
factors and cytokines (Faglia & Spada 2001, Asa & Ezzat 2002).
It has been demonstrated that neurons from hypothalamic
nuclei and posterior pituitary produce CXCL12, which could
modulate AVP secretion induced by autocrine mechanism
(Callewaere et al. 2006, 2007). From our immunohisto-
chemical analyses showing that anterior pituitary glands did
not express CXCL12 but CXCR4, the function of anterior
pituitary cells might be controlled by external CXCL12
originating fromhypothalamic neurons or systemic circulation
via blood vessels (Barbieri et al. 2007). Disruption of these
putative pathways related to CXCL12/CXCR4 interactions
might play a role in the development of pituitary adenoma.
Further studies are required to prove this hypothesis.
In conclusion, we investigated the expression of CXCR4
and CXCL12 and their physiological roles in normal rat
pituitary cells and GH-producing GH3 tumor cells.
CXCL12/CXCR4 interaction plays an important role in
the synthesis and release of GH and cell proliferation. These
results may suggest that CXCL12/CXCR4 signaling could
be a promising target for the treatment of GH-producing
pituitary tumors, and should be considered in future studies.Declaration of interest
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